Previous studies indicate that cyclin D2 promoter methylation is more extensive in malignant than nonmalignant human prostate tissue [31] and treatment with 5-Aza-dC and TSA increased cyclin D2 expression in prostate cancer cell lines [30]. The gene discussed is CCND2; the disease is prostate carcinoma.